Tumor necrosis factor-alpha mediates changes in tissue protein turnover in a rat cancer cachexia model. by Costelli, Paola et al.
Tumor Necrosis Factor-a Mediates Changes in Tissue Protein Turnover
in a Rat Cancer Cachexia Model
Paola Costelli, * Neus Carbo, Luciana Tessitore, * Gregory J. Bagby,' Francisco J. Lopez-Soriano,I Josep M. Argiles,' and
Francesco M. Baccino**
*Dipartimento di Medicina ed Oncologia Sperimentale, Sezione di Patologia Generale, Universitd di Torino, and tCentro Consiglio
Nazionale delle Ricerche di Immunogenetica ed Oncologia Sperimentale, 10125 Torino, Italy, §Departamento de Bioquimica y
Fisiologia, Universidad de Barcelona, 08071 Barcelona, Spain; 'Department ofPhysiology, Louisiana State University Medical Center,
New Orleans, Louisiana
Abstract
Rats bearing the Yoshida AH-130 ascites hepatoma showed
enhanced fractional rates of protein degradation in gastrocne-
mius muscle, heart, and liver, while fractional synthesis rates
were similar to those in non-tumor bearing rats. This hypercata-
bolic pattern was associated with marked perturbations of the
hormonal homeostasis and presence of tumor necrosis factor in
the circulation.
The daily administration of a goat anti-murine TNF IgG to
tumor-bearing rats decreased protein degradation rates in skele-
tal muscle, heart, and liver as compared with tumor-bearing
rats receiving a nonimmune goat IgG. The anti-TNF treatment
was also effective in attenuating early perturbations in insulin
and corticosterone homeostasis. Although these results suggest
that tumor necrosis factor plays a significant role in mediating
the changes in protein turnover and hormone levels elicited by
tumor growth, the inability of such treatment to prevent a re-
duction in body weight implies that other mediators or tumor-
related events were also involved. (J. Clin. Invest. 1993.
92:2783-2789.) Key words: tumor necrosis factor - skeletal
muscle * protein turnover * cachexia
Introduction
Loss ofbody weight and cachexia are common signs associated
with neoplastic diseases. Cachexia is a poorly understood syn-
drome characterized by anorexia, profound metabolic abnor-
malities, and progressive host wasting that results in death ( 1-
3). Tissue wasting mainly involves skeletal muscles and adi-
pose tissue. Numerous reports attribute the development ofthe
cachectic state to the release of cytokines, such as TNF (for a
review, see reference 4).
TNF is primarily produced by activated macrophages in
response to invasive stimuli. It belongs to a polypeptide net-
work made up ofseveral cytokines and growth factors that have
wide and varied effects on the growth, differentiation, and
functions of the immune system, as well as of other cells and
tissues (5, 6). Chronic treatment of rats with recombinant
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TNF results in depletion of body protein, as compared with
pair-fed control animals (7), and redistribution of body pro-
tein associated with significant muscle protein depletion and
coordinated decreases in muscle mRNAs for myofibrillar pro-
teins (8). The administration of recombinant TNF enhances
the nitrogen efflux from skeletal muscle in non-weight losing
humans with disseminated cancer (9), as well as muscle pro-
tein breakdown in rats (10). In vitro proteolytic rates in mus-
cles isolated from rats receiving a single dose ofTNF have been
reported either unchanged (I I) or increased ( 12).
Rats bearing the ascites hepatoma Yoshida AH- 130 offer a
suitable model system for investigations into the mechanisms
that lead to cancer cachexia. Previous work has shown that
tumor growth rapidly elicits in the host rat a conspicuous body
weight loss associated with a hypercatabolic state in tissue pro-
tein ( 13, 14). Marked perturbations in the hormonal homeosta-
sis develop early after tumor implantation, together with in-
creased levels of prostaglandin E2 and detectable TNF in
plasma ( 15). It thus appeared of interest to explore the role
played by TNF in this experimental model ofcancer cachexia.
The aim ofthe present investigation was to evaluate the involve-
ment of this cytokine in mediating the changes in muscle pro-
tein turnover in AH- 130 tumor-bearing rats through the ad-
ministration ofa goat polyclonal anti-murine TNF IgG. Such a
treatment both abolished any detectable free TNF in the
plasma and afforded a significant preservation of muscle pro-
tein, thus supporting a causative role for TNF as a mediator for
cachexia in this experimental model.
Methods
Biochemicals. Sodium ['4C]bicarbonate (specific activity 53 mCi/
mmol) was obtained from Amersham (Braunschweig, Germany).
Animals, tumor, and anti-TNF treatment. Male Wistar rats
(Charles River, Como, Italy) were fed ad libitum on a chow diet (Pic-
cioni, Brescia, Italy) consisting by weight of 49% carbohydrate, 20%
protein, and 5% fat (the residue was nondigestible material). Animals
had free access to drinking water and were maintained at an ambient
temperature of22°C under a 12-h light/ 12-h dark cycle (light on from
08:00 h).
A suspension ofYoshida AH- 1 30 ascites hepatoma cells ( 10 8 in
2 ml) was injected intraperitoneally (cf 13), while the control rats
received 2 ml of 0.9% (wt/vol) NaCl solution. Food intake and body
weight were measured daily after tumor inoculation.
Tumor-bearing animals either received no treatment or were given
daily (09:00 h) subcutaneous injections of 25 mg/kg body wt of a
polyclonal goat anti-murine TNF IgG preparation (anti-TNF) or of a
nonimmune goat IgG preparation (IgG). Treatments started the day
after tumor transplantation and lasted 6 d. No significant differences
were observed in the daily food intake among untreated animals, or
rats receiving nonimmune IgGs or anti-TNF IgGs.
Polyclonal goat anti-murine TNF IgGs were prepared using the
Ribi adjuvant system containing 0.5 mg each ofmonophosphoryl lipid
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A, trehalose dimycolate, and cell wall skeleton in 0.2% Tween 80 (Ribi
ImmunoChem. Res., Inc., Hamilton, MT). The serum IgG fraction
was obtained by polyethylene glycol precipitation and column chroma-
tography with DEAE Bio-Gel A (Bio-Rad Laboratories, Richmond,
CA). The neutralizing capacity of the anti-TNF IgG fraction in the
L929 cytotoxicity assay was 6.5 and 9.0 X 105 50% neutralizing units/
mg IgG against recombinant MiTNF-a and serum TNF from LPS-
treated rats, respectively. Nonimmune goat IgGs were prepared in the
same way and had no detectable TNF neutralizing activity (16). Nei-
ther IgG preparation demonstrated effective binding to LPS, IL-1, or
interferon-y in an ELISA protocol.
Plasma metabolites. Circulating insulin and corticosterone were
determined using the insulin (Coming Inc., Medfield, MA) and the rat
corticosterone (IDS, Boldon, England) radioimmunoassay kits, respec-
tively. Plasma TNF was measured using both the L929 cytotoxicity
assay (17) and an ELISA test (Genzyme Corp., Cambridge, MA).
Anti-TNF titers were estimated using an ELISA test (16).
Tissueprotein turnover. In vivo protein turnover was determined as
previously described (13). For this purpose, animals were injected in-
traperitoneally with 400,gCi/kg body wt with NaH 14CO3, dissolved in
0.15 M NaCl, 24 h before time 0, and killed on days 0, 4, and 7 after
tumor inoculation. Liver, kidneys, gastrocnemius, and heart were rap-
idly weighed and homogenized to 10% (wt/vol) in chilled water and
then frozen to -20°C. Total protein content was determined by the
method of Lowry et al. (18). Trichloroacetic acid-insoluble proteins
were processed for lipid extraction, extensively hydrolyzed, and
counted in a liquid scintillation spectrometer (cf 13). Total and spe-
cific (per milligrams of protein) protein radioactivity were determined
for gastrocnemius muscle, heart, kidneys, and liver. Fractional rates of
protein synthesis (kA), protein degradation (kd), and protein accumu-
lation (kA) were calculated (19, 20) by the following equations:
k, = ln (specific protein radioactivity)t-'
kd = ln (total protein radioactivity)t-'
kA = ln (total protein)t'
kA, = k, -kd
and expressed as percent per day, while t/12 (=ln 2/kd) was given in
days. The procedure adopted in studying protein radioactivity decay,
with time 0 corresponding to 24 h after administration of the label,
only takes into account the long-lived pool of tissue proteins, which
represents the large majority of the protein mass.
Data presentation. Data are means±SEM. Significance of the dif-
ferences was calculated by analysis of variance.
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Figure 1. Plasma TNF and anti-TNF levels in AH- 130 tumor-bearing
rats. Anti-TNF titers (-n). TNF levels in untreated (o), nonimmune
IgGs (a), or anti-TNF-treated tumor hosts (Co). Data are
means±SEM (n = 3-6).
Results
Tumor growth and body weight. The Yoshida AH- 130 ascites
hepatoma is a fast growing tumor: after an inoculum of 108
cells, the growth was exponential for 4-5 d with a population
doubling time of 23 h, followed by a stationary phase from day
7 until death ofthe animals (cf 13). By day 4 after inoculation,
the tumor-bearing rats exhibited a diminished gain in body
weight, and by day 7, their body weights were less than their
initial body weights (Table I). During this period, there was a
progressive increase in tumor volume (Table I). The anti-TNF
treatment did not significantly affect such changes.
The tumor mass (total cell wet weight) represented only 2.0
and 4.7% of host body weight on days 4 and 7, respectively.
Thus, changes in body weight can not be explained by growth
oftumor mass by itself. The number oftumor cells was moder-
ately decreased on day 4 in anti-TNF-treated animals, but this
effect was transient and not present on day 7 (Table I).
Anti-TNF titer, TNF level, and plasma hormones. Anti-
TNF antibodies and TNF were measured in the plasma and
Table I. Body Weight and AH-130 Tumor Volume and Cellularity
Body wt Tumor
Time Treatment Initial Final Volume Cells X 10-6
g
Day 4
Controls None (3) 167±2 193±5
Tumor bearers None (7) 167±3 179±4 15±2 2,309+76
IgG (4) 163±5 172±5 17±3 2,151±157
Anti-TNF (3) 164±2 173±4 14±5 1,747+241*
Day 7
Controls None (3) 167±2 228±1
Tumor bearers None (6) 166±4 148±5 54±7 4,682±157
IgG (3) 165±6 151±6 51±1 4,188±320
Anti-TNF (5) 165±5 154±6 54±6 5,001+200
Body weight is exclusive of tumor weight. Data are means±SEM for the number of animals given in parentheses. Significance of differences: * P
< 0.05 vs untreated tumor bearers.
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Figure 2. TNF and
anti-TNF levels in the
ascitic fluid of AH- 130
hosts. Anti-TNF titers
(.). TNF levels in un-
treated (0), nonim-
mune IgGs (am), or anti-
TNF treated tumor
hosts (v). Data are
means±SEM (n = 3-6).
ascitic fluid of tumor-bearing animals given a daily dose of
anti-TNF IgG, saline, or nonimmune IgG from 1 to 7 d after
tumor transplantation. Plasma anti-TNF IgG (Fig. 1) re-
mained steady between days 3 and 7, while their titer was some-
what higher in the ascitic fluid (Fig. 2). TNF (Fig. 1) was
detectable in the serum of untreated tumor bearers after the
first day of tumor transplantation and progressively increased
during the tumor log growth phase. After day 4, levels stabi-
lized regardless of the tumor burden or proliferative state, as
noted previously ( 15). In the ascitic fluid TNF attained levels
53-60% higher than in serum (Fig. 2), as one would expect if it
was mainly produced intraperitoneally (cf 15). The administra-
tion ofanti-TNF antibodies abolished any detectable free TNF
in both serum (Fig. 1) and ascitic fluid (Fig. 2), while nonim-
mune IgGs had no effect.
Plasma insulin decreased while corticosterone increased in
response to tumor growth (Fig. 3), in agreement with previous
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Figure 3. Blood plasma
levels of insulin (A) and
corticosterone (B).
Data are means±SEM
(n = 3-6) in controls
(c) and in AH-130
hosts either untreated
(m) or treated with non-
immune IgGs (in), and
anti-TNF antibodies
(i). Significance of the
differences: a = P
< 0.01 vs controls; b
= P < 0.05 anti-TNF
treated AH- 130 hosts
vs untreated or IgGs
treated groups.
observations (15). Treatment with anti-TNF antibodies pre-
vented the tumor-induced alterations on day 4, but by day 7,
only insulin was still slightly higher than in nonimmune IgG-
treated animals, while corticosterone did not differ between the
three groups of animals.
Tissue wet weight and protein content. Tissue wet weight
and protein data (Table II) are referred to 100 g ofinitial body
weight for the purpose of standardization (cf20). The gastroc-
nemius protein mass and wet weight were considerably com-
promized by tumor growth and the anti-TNF treatment signifi-
cantly improved these parameters on both days 4 and 7, al-
though the values still remained lower than in nontumor
Table II. Tissue Weight and Protein in AH-130 Tumor-bearing Rats
Day4 Day 7
Tumor bearers Tumor bearers
Tissue Controls None IgG Anti-TNF Controls None IgG Anti-TNF
Muscle 631±9 509±12 516±22 558±9 660±17 476±22 483±21 567±26
(3) **(7) **(3) **(4)t (3) **(6) **(3) *(5)$
Protein 59.4±0.9 47.4±2.5 51.3±1.5 52.8±1.1 64.5±0.7 39.2±3.1 40.3±1.4 53.2±2.3
(3) *(7) **(4) **(3) (3) **(6) **(3) (4)t**§
Heart 395±18 324±11 305±10 303±8 391±9 255±7 249±13 248±14
(3) **(7) **(3) **(4) (3) **(6) **(3) **(5)
Protein 47.3±3.7 37.6±3.0 45.7±1.7 50.0±2.6 50.4±3.0 32.6±3.2 42.9±1.3 41.7±0.9
(3) **(5) (4)tt (4)4* (3) **(6) (3) *(4)$
Liver 5,532±94 4,898±157 4,910±123 4,773±235 6,711±11 4,411+100 4,776+174 5,234±252
(3) *(7) *(3) *(3) (3) **(6) **(3) **(5)**
Protein 1,132±12 898±27 942±43 894±27 1,432+43 865±19 932±14 988±73
(3) **(5) *(4) **(4) (3) **(6) **(3) **(5)
Kidney 1,008±47 880±13 841±18 820±40 1,124+36 742±12 811±23 793±34
(3) *(7) *(3) *(4) (3) **(6) **(3) **(5)
Protein 246±18 198±8 199±7 191±10 277±21 170±11 173±13 178±14
(3) **(7) **(3) **(4) (3) **(6) **(3) **(5)
Data are means±SEM for the number of animals indicated in parentheses. Tissue wet weight and total protein expressed as milligrams per 100 g
initial body wt. Statistical significance of the differences: * tumor bearers vs controls (untreated non-tumor bearers); * nonimmune IgG- or
anti-TNF-treated vs untreated tumor bearers; § nonimmune IgG vs anti-TNF treatment. *$ P < 0.05; **tt§ P < 0.01.
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bearers. Heart wet weight and protein content, both sharply
decreased in untreated tumor bearers, were partially restored
by treatment with anti-TNF, as well as with nonimmune IgGs
on day 4 after transplantation, while only the former treatment
was still effective on day 7 (Table II). Wet weight and protein
content of liver and kidney decreased in tumor hosts, and the
anti-TNF treatment did not induce any significant change in
these parameters with respect to nonimmune IgG-treated ani-
mals.
Tissue protein turnover. To evaluate the effects of tumor
growth and anti-TNF treatment on tissue protein turnover,
AH- 130 tumor-bearing animals were given a single dose of
NaH 14CO3 24 h before tumor transplantation, then the total
and specific radioactivity, as well as the total content of tissue
protein, were measured on days 0, 4, and 7 oftumor growth (a
detailed analysis of this procedure has been presented else-
where: reference 13). A single radioactive precursor was used
for all of the tissues investigated. This in vivo protein labeling
technique is most suitable for liver (21 ), but is limited by recy-
cling in skeletal muscle (22). However, fractional rates of pro-
tein accumulation obtained by difference between fractional
rates of synthesis and degradation (kal = ks - kd) usually ap-
proximately match those calculated directly from changes in
total protein (ka), as shown in Table III. The 24-h lag between
the administration of NaH '4CO3 and the first experimental
time (day 0 of tumor growth) was adequate to exclude from
measurements the fast turnover protein pool, as well as secre-
tory proteins; thus, this experimental protocol only evaluates
the slow-turnover protein pool(s) ( 13 ). The protein turnover
rates and the t/2 measured over the two observation windows
(days 0-4 and days 4-7, respectively) were quite different for
liver and kidney because ofthe heterogeneous half-lives ofpro-
teins of the slow turnover pool(s) (cf 23), while they were
practically identical for muscle and heart; therefore, only data
for the 0-7-d interval are presented for skeletal muscle and
heart.
The effects of the anti-TNF treatment on protein synthesis
and degradation in muscle and other tissues of tumor bearers
are summarized in Table III. The skeletal muscle, which repre-
sents the major protein mass, was markedly affected in AH- 130
Table III. Effect ofAnti-TNF Treatment on Tissue Protein Turnover in AH-130 Tumor-bearing Rats
Treatment Days k. kd k k., t1/2
Muscle
Controls 0-7 11.60 5.63 5.14 5.97 12.31
AH- 130 hosts
None 0-7 12.01 13.86 -1.97 -1.85 5.00
IgG 0-7 11.91 13.02 -1.58 -1.11 5.32
Anti-TNF 0-7 11.34 8.18 2.39 3.16 8.47
Heart
Controls 0-7 6.92 4.96 2.13 1.81 13.97
AH- 130 hosts
None 0-7 5.99 12.98 -4.09 -6.99 5.34
IgG 0-7 6.84 9.86 -0.17 -3.02 7.03
Anti-TNF 0-7 6.32 9.75 -0.57 -3.43 7.11
Liver
Controls 0-4 27.57 20.18 7.82 7.39 3.43
4-7 15.77 13.02 7.83 2.57 5.32
AH- 130 hosts
None 0-4 30.92 26.84 2.03 4.08 2.58
4-7 13.62 20.36 -1.25 -6.74 3.40
IgG 0-4 31.17 27.06 3.22 4.11 2.56
4-7 15.35 17.08 -0.05 -1.73 4.06
Anti-TNF 0-4 24.76 20.73 1.92 4.03 3.34
4-7 11.86 10.77 3.33 1.09 5.84
Kidney
Controls 0-4 23.33 19.27 4.19 4.06 3.60
4-7 11.95 8.44 3.95 3.51 8.22
AH- 130 hosts
None 0-4 23.55 24.96 -1.23 -1.41 2.78
4-7 8.95 12.06 -5.08 -3.11 5.77
IgG 0-4 22.25 24.86 -1.11 -2.61 2.79
4-7 8.60 11.39 -4.67 -2.79 6.09
Anti-TNF 0-4 19.61 21.86 -2.13 -2.26 3.17
4-7 9.61 10.26 -2.35 -0.65 6.77
Rates of protein synthesis (ks), degradation (kd), and accumulation (k', ka) expressed as percent per day, t,12 in days, and assessed on the 0-7-
d interval for gastrocnemius and heart or 0-4- and 4-7-d intervals for liver and kidneys. k. and kd calculated from the decay of specific and total
protein radioactivity (means of three to seven data per ech time point, with SEM usually within 10% of the mean) after labeling with NaH"4CO3,
ka from changes in total protein, while ka, = k, - kd. For further details, see Methods.
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tumor-bearing rats. Protein waste implies an imbalance be-
tween synthesis and degradation. While the fractional synthesis
rates (ks) showed little change in the gastrocnemius and heart
as a result oftumor growth, fractional rates ofprotein degrada-
tion (kd) were markedly elevated, viz, 2.5-fold for gastrocne-
mius and 2.6-fold for heart, thus protein losses (ka, and ka) in
both tissues have to be mostly accounted for by the latter
change. The anti-TNF treatment decreased protein degrada-
tion in the gastrocnemius, as compared with the animals re-
ceiving nonimmune IgGs and, as a result, protein accumula-
tion was improved, although the values were still lower than in
non-tumor bearers. Surprisingly, anti-TNF antibody and non-
immune IgGs had similar effects in slowing down protein degra-
dation and improving protein accumulation in the heart.
In the liver, a slight increase in synthesis rates and an im-
portant increment in degradation rates were observed for both
0-4-d and 4-7-d intervals after tumor transplantation; conse-
quently, the hepatic protein mass was markedly affected. The
anti-TNF treatment decreased both synthesis and degradation
rates to a similar degree in the first interval (0-4 d) so that
protein loss was not evident. The anti-TNF treatment pro-
duced a marked reduction in protein degradation in the second
observation period (4-7 d) to rates that were not different from
those measured in non-tumor bearing controls. Liver protein
was thus significantly preserved. Similar results occurred in the
kidneys, but the effects of the anti-TNF treatment were less
pronounced in this tissue.
Discussion
TNF has been proposed as an important mediator of cachexia
(4, 5, 24, 25). Its role in cancer cachexia has been very contro-
versial. No significant correlation was observed between sever-
ity of weight loss and serum TNF levels in cachectic patients
(26). When given repeated injections of TNF, experimental
animals develop tachyphylaxis, i.e., become progressively de-
sensitised to the anorectic/cachectic action of the cytokine,
and increasing daily doses ofTNF are required to maintain the
same effects (7). This phenomenon does not occur, however, if
TNF is given by continuous infusion rather than by sporadic
injections (27) or in nude mice implanted with Chinese ham-
ster ovary cells transfected with the human TNF gene, which
thus develop a profound cachectic state (28).
The ascites hepatoma Yoshida AH- 130 causes early and
progressive tissue waste in the host rats, by producing an unbal-
ance in protein turnover towards the catabolic side ( 13 ). Such
a pattern is associated with marked alterations in the hormonal
homeostasis and occurrence of persistent TNF levels in the
circulation ( 15). The present paper shows that administration
of anti-TNF antibodies to these rats neutralized circulating
TNF, thus making this a particularly interesting model to exam-
ine its possible involvement in cancer cachexia. A note of cau-
tion is suggested by the observation that the anti-TNF treat-
ment resulted in a transient, slight reduction in the tumor cell
number 4 d after transplantation. Whether this reflected the
decreased availability of TNF as a possible autocrine growth
factor for these tumor cells (cf 15) or a diminished availability
of nutrients (cf 29) caused by the anticatabolic effects of the
anti-TNF treatment or some other mechanism, it is difficult to
establish at the moment. However, the observed reduction in
tumor size on the one hand was too small to have exerted any
significant effect on host metabolism (cf 13), on the other was
quickly overcome and no longer detectable on day 7 of tumor
growth.
In a another paper (Carbo, N., P. Costelli, L. Tessitore,
G. J. Bagby, F. J. Lopez-Soriano, F. M. Baccino, and J. M.
Argiles, submitted for publication), we have shown that treat-
ment with anti-TNF antibody significantly interfered with the
development of perturbations of lipid metabolism and adipose
tissue waste in AH- 130 tumor-bearing rats. The present obser-
vations further show that treating the AH- 130 tumor-bearing
animals with anti-TNF antibody had appreciable effects on
protein turnover in all of the tissues examined, namely, gas-
trocnemius, heart, liver, and kidney. In general, the anti-TNF
treatment was adequate to decrease the enhanced rates of pro-
tein degradation. By contrast, synthesis rates were little or neg-
ligibly affected by tumor growth and the anti-TNF treatment
did not introduce any change, except in the liver, wherein a
decrease in the synthesis rate was observed. Although not de-
tected in the present experiments, likely because of the single
time point selected (day 4), a transient enlargement of the liver
during the very first days of AH- 130 tumor growth is usually
observed: a change associated with enhanced protein synthesis
( 13). This may reflect, in part at least, an acute phase reaction
(see below). The reduction in hepatic protein synthesis af-
forded by the anti-TNF treatment may thus correspond to an
interference with the late stages of such changes. In spite of the
improved protein turnover patterns observed in all tissues ex-
amined, only the gastrocnemius benefitted with a significant
preservation ofprotein mass by the anti-TNF treatment in com-
parison with untreated or nonimmune IgG-treated tumor
bearers. Moreover, the anti-TNF treatment did not afford any
significant preservation of the body and carcass weight. Al-
though the present data do not provide any clue to account for
this apparently paradoxical finding, a decreased water reten-
tion in anti-TNF-treated rats seems a likely explanation (cf 7,
24, 30). The fact that the anti-TNF treatment has greater ef-
fects in the early phases of tumor growth as compared to late
strongly suggests that TNF is not the only mediator involved in
cachexia. The effects exerted by the anti-TNF antibodies ad-
ministration, in particular the delaying of the decrease in insu-
lin and increase in corticosterone plasmatic levels (cf 15), also
support the idea that this cytokine may be important during
the first days after tumor transplantation, probably altering the
hormonal homeostasis towards a catabolic pattern.
The present observations strongly support an involvement
ofTNF in the development of cancer cachexia and, in particu-
lar, a role for this cytokine in mediating the alterations of pro-
tein metabolism. This is in keeping with previous reports on
rats transplanted with a methylcholanthrene-induced sarcoma
and rendered tolerant to TNF through repeated administra-
tions of low doses of the cytokine (31 ) or on mice bearing the
sarcoma MCG- 101 treated with anti-TNF antibodies (32). Of
interest, in the latter model, tumor cells themselves produced
the cytokine, yet cachexia developed without any measurable
plasma TNF (33), suggesting that this mediator might be im-
portant even at concentrations below the present levels of de-
tectability.
A role for TNF in altering tissue protein metabolism has
been suggested by a number of reports. Thus, a single dose of
recombinant human TNF to rats resulted in increased muscle
proteolysis ( 10), while rats given the cytokine on a chronic
schedule lose total body protein at rates higher than pair-fed
controls (7). TNF administration augmented the amino acid
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release from peripheral tissues in cancer patients (9), and mus-
cle protein degradation was accelerated by TNF given at doses
smaller than those required to produce hemodynamic changes
(34). In vitro work also seems to implicate TNF in enhancing
protein degradation ( 12), although evidence for its direct me-
diation of this effect remains elusive (1 1, 35, 36). In the liver,
TNF is able to enhance protein synthesis (37), to increase the
proportion of mRNA species for serum albumin and acute
phase proteins (38), and to stimulate the uptake of a-amino-
isobutyrate, a nonmetabolizable analogue of alanine (39).
It has been suggested that TNF may accelerate muscle pro-
tein catabolism by stimulating the release of adrenocortical
hormones or interacting with them (40, 41 ). Such a possibility
is compatible with the high levels ofcorticosterone occurring in
rats bearing the Yoshida AH- 130 hepatoma ( 15), as well as
with their reduction on anti-TNF treatment, as shown by the
present data. The same possibility applies to insulin, which
markedly decreased in tumor bearers and was partially or to-
tally restored to normal levels by the anti-TNF treatment. In
this regard, the concurrent administration ofinsulin with TNF
was shown to modulate the toxic effects ofTNF on rats (27). In
principle, an improvement in the nutritional state of tumor
hosts could have been a predictable consequence of the anti-
TNF treatment, yet the food intake in anti-TNF-treated ani-
mals was not increased with respect to untreated or nonim-
mune IgG-treated experimental groups, thus ruling out this
possible explanation for the anti-TNF effects. This finding pro-
vides further support to the view, derived from our previous
work, that decreased food intake is unlikely to play a primary
role in the development of cachexia in AH-130 tumor hosts
( 15). The only exception was the heart, wherein protein loss in
tumor bearers was comparable to that in pair-fed controls ( 14).
The results presented here definitely implicate TNF in the
changes of protein metabolism associated with the growth of
the Yoshida AH- 130 hepatoma. However, in these as well as in
other experiments (Carbo, N., P. Costelli, L. Tessitore, G. J.
Bagby, F. J. Lopez-Soriano, and J. M. Argiles, manuscript sub-
mitted for publication) the anti-TNF treatment was far from
affording a complete protection, not even in the initial phases
oftumor growth. Other humoral factors have been postulated
to concur in mediating cancer cachexia in other models.
Among the most recent reports, severe cachexia is induced by a
muscle proteolytic factor produced by the murine colon adeno-
carcinoma MAC 16 (42) or develops in nude mice implanted
with different melanoma cell lines producing the leukemia in-
hibitory factor (43) or with Chinese hamster ovary cells trans-
fected with human IFN-,y cDNA (44). Moreover, Matthys et
al. (45) have observed that the development of cachexia in
mice bearing the Lewis lung carcinoma can be prevented by the
administration of anti-IFN-'y antibodies. Therefore, the pres-
ent observations by no means can lead to the conclusion that
TNF is the sole mediator of cancer cachexia, not even in the
present model system.
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